BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.
2 reports, 1 independent
Updated Sep 7
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company
-
Nasdaq
American fully electronic stock exchange
Related events
- The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.
- BioNTech pulled the plug on the Phase 2 clinical trial involving Hoffmann-La Roche.
- Genentech collaboration supports Duality Biotherapeutics' DUPAC platform confidence.
- Hoffmann-La Roche collaborates with Singaporean institutions, including NUS and NRF, on genomic profiling research to accelerate precision medicine.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.